Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 3/2015

THE CURRENT INSIGHT ON DUAL RENIN-ANGIOTENSIN SYSTEM BLOCKADE: A DATA REVIEW WITH A FOCUS ON

ANDREEA FARCAȘ1, FELICIA GLIGOR2*, CAMELIA BUCȘA1, CRISTINA MOGOȘAN1, MARIUS BOJIȚĂ1, DAN DUMITRAȘCU3

1.Iuliu Hațieganu University of Medicine and Pharmacy, Drug Information Research Center, Pasteur 6, 400349, Cluj-Napoca, Romania
2.Lucian Blaga University Sibiu, Faculty of Medicine, Lucian Blaga, 2A, 550169, Sibiu, Romania
3.Iuliu Hațieganu University of Medicine and Pharmacy, 2nd Medical Department, Clinicilor 2-4, 400013, Cluj-Napoca, Romania

Download Full Article PDF

The renin-angiotensin system (RAS) inhibition plays an important role in the therapeutic approach of the hypertensive patient, including the prevention of cardiovascular and renal complications disease. For an enhanced clinical effect, there is a strong biological rationale for dual therapy with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), dual therapy that has been embraced by many clinicians to obtain a more complete RAS blockade, offering cardioprotection and renoprotection. However, clinical trials conducted throughout the last decade have provided conflicting results regarding the benefits and safety of RAS dual blockade in patients with hypertension, heart failure, ischemic heart disease, renal disease or diabetes. In fact, dual therapy did not reduce mortality, but it was associated with an increased harm, thus pleading against the use of this association. The present review aims to be an appraisal of the latest evidence on dual renin-angiotensin system blockade, with a focus on safety.